



SUBJECT:

MEDIA ANNOUCEMENT

RELEASE:

FOR IMMEDIATE RELEASE – 08.00 HRS 14.03.2017

REGION:

EMAIL ENQUIRES: media@artcapman.com

FOLLOW US:

TWITTER: <https://twitter.com/artcapman/status/841370461778919425>

Arterial Capital Management have today released their internationally respected, annual review of the key demographic and political drivers and financial activity within the pharmaceutical, medtech and biotech sectors.

About the Arterial Annual Review of 2016 Healthcare:

Arterial Capital Management's annual review of 2016 global healthcare is considered by many family offices, research analysts and wealth management groups to be the leading, authoritative report on the economic and political drivers and activity within the life science sector.

Arterial Capital Management, gained from first-hand experience, provide readers with an in depth analysis of the past years' investment trends within biotech, medtech and pharmaceuticals, analyse deal flow between private and institutional investors, identify trends by sub sector, product and geographical / regional placement and conclude with their predictions for the year and decades ahead.

About Arterial Capital Management:

Arterial Capital Management is a private equity firm focused exclusively on the global life science sector. We specialise in providing equity funding to biotech, medtech and pharmaceutical companies. We typically invest our own money into each project on the same terms as other investors and are motivated primarily by a 20% carried interest on the successful realisation of a holding. Investment deal size is typically £5-25m.

Markus Weissbach, Director of Clinical Trials said:

"I am delighted that our research team have worked so hard to produce the 2016 review in record time. Arterial's annual review of global life science provides professional advisors around the globe with a dependable, reliable source of data."

David Evans, Director of Intellectual Property said:

"We believe that the Arterial Capital Management's annual review has become the most respected annual review of healthcare and life science. Importantly, Arterial's analysis is based on first-hand experience, of a globally recognised team"

Mickael Marsali, Co-Founder of Arterial said:

"Professional advisers, whether they are pension funds, family offices or IFAs need reliable and trustworthy data for their clients. Life science offers immense opportunities for uncorrelated alpha. The Arterial annual report is unequivocally a key component of any sector review by professional advisory and wealth management firms."

Media representatives requiring exclusive quotes or response to interview questions should email media@artcapman.com



@artcapman



www.linkedin.com/company/arterial-capital-management



www.facebook.com/artcapman